A. Menarini Pharma GmbH ist eine österreichische Tochtergesellschaft der Menarini Group/Florenz.
Lesen Sie die neuesten Nachrichten von der Menarini Gruppe.
A. Menarini Pharma GmbH is an Austrian subsidiary of the Menarini Group/Florence.
Read the latest news from the Menarini Group.
The skin covers the entire body and is therefore the largest organ of the human body. Accordingly, the field of dermatology is also versatile and wide-ranging. The skin protects the body from environmental influences. It is often affected by these, but also by internal factors. If a patient is affected by a skin disease, the level of suffering is often high due to possible aesthetic effects. The company A. Menarini Pharma GmbH covers two common skin diseases with its preparations for the two indications herpes zoster and urticaria.
Herpes zoster – timely therapy counts
Herpes zoster is a neurocutaneous disease that occurs more frequently after the age of 50 and is characterized by the formation of blisters on one side of the body, usually limited to one dermatome. Older patients in particular are at increased risk for chronic pain due to damage to the nervous system caused by varicella-zoster virus (VZV). The sequelae of chronicity (postzoster neuralgia, PZN) significantly impair quality of life. Early antiviral systemic therapy of shingles can lead to rapid healing of skin florescences and reduce zoster-associated pain, as well as the risk of PZN.
Urticaria – when the skin itches
Hives typically present with skin redness and wheals and are accompanied by itching. The causes are varied, but the activation of mast cells initiated by the body and thus the release of histamine is always the trigger for the skin changes. There are different forms of urticaria such as spontaneous acute urticaria, spontaneous chronic urticaria (duration of symptoms longer than 6 weeks) or physical forms (triggers include cold, heat or pressure). Systemically acting antihistamines, for example in the form of tablets, are the drug of choice for alleviating the symptoms. For further information on our products, dear doctor or pharmacist, please use your Doc-Check access data.
AT-WEB-45-10-2021
LEARN MORE
Here you will find information about your continuing education in dermatology.